NGNE: Reloading at the BC ZoneNeurogene Inc.BATS:NGNESmellyTazAfter sweeping its prior bearish Point C target, NGNE carved out a definitive macro bottom and launched a powerful new bullish cycle. The initial surge to Point A was backed by heavy fundamental momentum—highlighted by promising Phase 1/2 trial data for its Rett syndrome gene therapy (NGN-401) and a cash runway extending into 2029. The corrective pullback into Point B held the Whole Correction Level (WCL) at $15.00 with surgical precision, fully validating the new structural foundation. Following a sharp expansion toward $45.00, price is now executing a textbook retracement straight into the primary bullish BC zone ($24.00–$28.00). This region marks a key technical sweet spot where sequence geometry intersects with clinical catalysts and commercial launch readiness, offering a clean structural area to digest the recent move. So long as price holds above structural invalidation at Point B, the macro sequence framework remains dominant. The ultimate target for this weekly expansion remains Point C around $70.00, situated directly inside the $65.00–$75.00 target block as the broader biotech growth thesis unfolds.